ChemRar High Tech Center
Manufacturing · Russia · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Rabochaya St 1 2A, Khimki, Moscow Oblast...Phone Number
+7 4959954944Website
www.chemrar.ruRevenue
$22.1 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About ChemRar High Tech Center
ЦВТ ХимРар is a pharmaceutical company dedicated to improving the quality of life by developing and producing effective, safe, and affordable medications for socially significant diseases. They offer a range of services including drug research and development, pharmaceutical formulation, and contract manufacturing of clinical batches. Their innovative products target various health issues, including central nervous system disorders, HIV, cardiovascular diseases, and viral infections. The company aims to leverage scientific and technological advancements to expedite the creation of new treatments, particularly in Russia and globally.Explore more
ChemRar High Tech Center Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ChemRar High Tech Center your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at ChemRar High Tech Center
Check if ChemRar High Tech Center has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on ChemRar High Tech Center recently announced quarterly report
Funding: Get notified immidiatlly once ChemRar High Tech Center has new funding data
Click to see if ChemRar High Tech Center had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if ChemRar High Tech Center is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
ChemRar High Tech Center, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when ChemRar High Tech Center launches new products
Recommended Actions
Find VP level buyers at ChemRar High Tech Center
Find 3 more new buyers
Company Profile Activity
Activity Insights
ChemRar High Tech Center is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ChemRar High Tech Center is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ChemRar High Tech Center.
ChemRar High Tech Center Tech Stack
A closer look at the technologies used by ChemRar High Tech Center
See more technologies
ChemRar High Tech Center News & Media
RDIF and ChemRar to supply Avifavir to 17 countries
Efficacy of favipiravir-based drugs against COVID-19 confirmed by clinical trials in Russia and Japan Avifavir already delivered to Belarus, Bolivia, Kazakhstan, Kyrgyzstan, Turkmenistan and Uzbekistan, deliveries to 17 more countries expected MOSCOW, Sept. 24, 2020 /PRNewswire/ -- The...RDIF and ChemRar Announce Increased Production of Avifavir for Treatment of Coronavirus and Begin Export Deliveries
The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and ChemRar Group produced the first 100,000 courses of the Russian coronavirus drug Avifavir in June, significantly exceeding initially planned production levels of 60,000 courses.Russians claim to have an effective treatment for the coronavirus, which hospitals will start using in June
Russia has approved an anti-influenza drug to treat Covid-19 and will start delivering courses of the drug, Avifavir, to hospitals in June, according to Russia's sovereign wealth fund (RDIF).RDIF and ChemRar to Deliver 60,000 Courses of the First COVID-19 Drug Registered in Russia, Avifavir, to the Country's Hospitals in June
The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and the ChemRar Group will deliver 60,000 courses of Avifavir to Russian hospitals in June. Avifavir is Russia's first COVID-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials. Avifavir has received a registration certificate from the Ministry of Health of the Russian Federation. Thus, Avifavir has become the first Favipiravir-based drug in the world approved for the treatment
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ChemRar High Tech Center
Sign Up For FreeTo access detailed company insights
ЦВТ ХимРар is a pharmaceutical company dedicated to improving the quality of life by developing and producing effective, safe, and affordable medications for socially significant diseases. They offer a range of services including drug research and development, pharmaceutical formulation, and contract manufacturing of clinical batches. Their innovat... Read More
